The Optimum Management of Arthropathies
- 8 Downloads
The aims in management of an arthropathy are to relieve symptoms, preserve function, and control the disease process. Drugs are an important, although not the only, part of any therapeutic regimen enabling us to achieve these aims.
Although each individual requires a unique strategy, there is a logical progression from first-line agents to second-line agents. Third-line agents and experimental methods are reserved for aggressive or life-threatening disease. The choice of agent in each group is personal preference, but many agents have high adverse effect profiles, and close moni-toring is essential.
KeywordsRheumatoid Arthritis Rheumatic Disease Arthropathy Septic Arthritis Levamisole
Unable to display preview. Download preview PDF.
- Anon. Fish oils in rheumatoid arthritis. Lancet 2: 720–721, 1987Google Scholar
- Ansell BM, Hall MA, Ribero S. A comparative study of gold and penicillamine in seropositive juvenile chronic arthritis. Abstract. Annals of the Rheumatic Diseases 40: 522–523, 1981Google Scholar
- Bird HA, Wright V. Applied drug therapy of the rheumatic diseases, John Wright, Bristol, 1982Google Scholar
- Boers M, Van Rijthoven AWAM, Goei The HS, Dijkmans BAC, Cats A. Serum creatinine levels two years later: follow-up of a placebocontrolled trial of cyclosporin in rheumatoid arthritis. Abstract. British Journal of Rheumatology 26 (Suppl. 2): 3, 1987Google Scholar
- Cooperating Clinics Committee of the American Rheumatism Association. A controlled trial of cyclophosphamide in rheumatoid arthritis. New England Journal of Medicine 283: 833–889, 1970Google Scholar
- European League against Rheumatism. Proceedings of the International Symposium on Levamisole in Rheumatoid Arthritis, Antwerp, June 23, 1978. Journal of Rheumatology 5 (Suppl. 4), 1978Google Scholar
- Fike MC. How occupational therapy can help your arthritis patient. Journal of Musculoskeletal Medicine 1: 51–58, 1984Google Scholar
- Huskisson EC. Antirheumatic drugs. Clinics in Rheumatic Diseases 5: 357–736, 1979Google Scholar
- Karsh J, Klippel JH, Plotz PH, Wright DG, Flye W, et al. Lymphoparesis in rheumatoid arthritis: a randomised trial. Arthritis and Rheumatism 23: 701–702, 1980Google Scholar
- Nacarro AH. Physical therapy in the management of rheumatoid arthritis. Clinical Rheumatology 1: 125–130, 1983Google Scholar
- Proceedings. Advances in arthritis therapy: experience with methotrexate, Anaheim, June 8, 1985. Journal of Rheumatology 12 (Suppl. 12), 1985Google Scholar
- Rainsford K. Side effects of anti-inflammatory/analgesic drugs: epidemiology and gastrointestinal tract. Trends in Pharmacological Sciences, April 1–4, 1984Google Scholar
- Spalton D. Chloroquine and the eye. British Journal of Clinical Practice 41 (Suppl. 52): 50–55, 1987Google Scholar
- Symoens J, Schuermans Y. Levamisole. Clinics in Rheumatic Diseases 5: 603–629, 1979Google Scholar
- Symposium on Radioactive Colloids in the Treatment of Arthritis. Annals of the Rheumatic Diseases 32 (Suppl.), 1973Google Scholar